The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Open accessAbstract
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA MRD results. Furthermore, the clinical utility of ctDNA MRD for treatment personalization remains to be fully established. Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and highlight key considerations in the application of this potentially transformative biomarker.Significance: ctDNA analysis enables detection of MRD and predicts relapse after definitive treatment for solid cancers, thereby promising to revolutionize personalization of adjuvant and consolidation therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [7]
In the citing paper
“although its clinical utility for directing treatment escalation or de-escalation remains under prospective evaluation [ 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Across early-stage solid tumors, postoperative or post-treatment ctDNA detection is consistently associated with a higher risk of recurrence”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“ctDNA analysis has developed most rapidly in common epithelial malignancies, where it is now used for selected advanced-cancer genotyping scenarios and is being actively evaluated for MRD and molecular relapse monitoring after curative-intent therapy [ 5 , 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“In early-stage solid tumors, ctDNA detection after curative-intent therapy has shown strong clinical validity for predicting future relapse”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Among liquid-biopsy analytes, ctDNA is currently the most clinically mature for sarcoma monitoring because it can capture tumor-specific genomic and epigenomic alterations through a minimally invasive and repeatable blood test [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection requires greater analytical sensitivity than baseline genotyping or advanced-disease resistance monitoring, because tumor-derived DNA may represent only a very small fraction of total cell-free DNA after definitive therapy [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can improve sensitivity by tracking patient-specific alterations identified from tissue sequencing”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“whereas tumor-naïve approaches may be useful when tissue is unavailable or when methylation, fragmentomic, or copy-number signals provide sufficient discriminatory power [ 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection is the most clinically ambitious use of ctDNA in sarcoma. It requires substantially greater analytical sensitivity than baseline genotyping because tumor-derived DNA may be present at very low levels after surgery or definitive therapy [ 5 , 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can track multiple patient-specific alterations at high depth, improving sensitivity for low-level residual disease [ 9 , 16 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Flagged first, then by citations
Research works printed but not linked: 1
- Pierson-Perry, 2012, Evaluation of detection capability for clinical laboratory measurement procedures: approved guideline
Cited by
Sorted by citations
Items 201–300 of 327
Pennell, N. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00827 · Cited by 3
Tokura, M., Ando, M. M., Kojima, Y., Kitadai, R., Yazaki, S., Atutubo, C. M. N., Li, R. K., Perez, M. Z., Gorospe, A. E., Madrid, M. A., et al. (2024) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234241288671 · Cited by 2
Landon, B. V., Huang, J., Evangelopoulou, E. G., Anagnostou, V., & Canzoniero, J. V. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.002 · Cited by 2
Wang, T., Lai, X., Wang, S., Xue, Z., Liu, Y., Zhu, X., Wang, X., Chang, Z., Shao, Y. W., Zhang, X., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf529 · Cited by 2
Murray, N. P., & Aedo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311346 · Cited by 4
SATO, H., Aoki, S., Iseki, M., Ando, M., Hayashi, S., Yoshimachi, S., Kusaka, A., Shimura, M., Douchi, D., Miura, T., et al. (2026) · BMC Surgery · doi:10.1186/s12893-025-03374-x · Cited by 2
Kahns, S., Zedan, A. H., Aagaard, M. M., do Canto, L. M., Kjær‐Frifeldt, S., Eriksen, S. V., Madsen, C. V., Madsen, J. S., Osther, P. J. S., Hansen, T. F., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340786 · Cited by 2
You, H., He, J., & Tian, T. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1735752 · Cited by 4
ctDNA monitoring using tumor-informed copy number analysis
Zhou, Z., Cutts, R., Hrebien, S., Zhang, C., García-Murillas, I., Zhang, W. Z., Frankell, A. M., Cooper, W. N., Roshan, A., Turner, N. C., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00399-4 · Cited by 3
Liu, Z., Yang, Y., Yu, B., Yang, Y., Yuan, C., Chen, C., Yang, X., Zhang, S., Li, C., Chao, Y., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.04.014 · Cited by 2
Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host
Ismaili, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847526 · Cited by 2
Organoid technology in cancer research
Zhang, J., & He, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00505-5 · Cited by 3
Cunningham, N., Cutts, R. J., Swift, C., Coakley, M. F., Sritharan, P., Dunne, K., Dewan, M., Kilburn, L., Goddard, K., Hall, P., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.2833 · Cited by 4
Clinical Applications for Liquid Biopsy Assessment of Minimal Residual Disease in Breast Cancer
Sears, J. J., & Davis, A. A. (2023) · Current Breast Cancer Reports · doi:10.1007/s12609-023-00489-z · Cited by 4
Lebow, E. S., Eichholz, J., Boe, L. A., Zhang, Z., Kratochvil, L. B., Gelblum, D. Y., Simone, C. B., Shepherd, A. F., Iyengar, P., Shin, J. Y., et al. (2025) · Advances in Radiation Oncology · doi:10.1016/j.adro.2025.101727 · Cited by 2
The Prognostic Value of FOXL2 Mutant Circulating Tumor DNA in Adult Granulosa Cell Tumor Patients
Brink, G. J., Hami, N., Nijman, H. W., Piek, J. M. J., van Lonkhuijzen, L. R. C. W., Roes, E. M., Hofhuis, W., Lok, C. A. R., de Kroon, C. D., Gort, E. H., et al. (2025) · Cancers · doi:10.3390/cancers17111894 · Cited by 2
Alkassis, S., Suresh, Y., Lipsyc-Sharf, M. D., Zhang, S., Gianni, C., Medford, A. J., Bardia, A., Ashouri, S., & Kapoor, N. S. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07773-9 · Cited by 2
CRC management: Emerging trends in early detection, diagnosis, biomarkers, treatment, and prevention
Alotaibi, A. G., Alfozan, B. A., Alotaibi, S. S., Mutairi, A. A., Humoudi, A. Y. A., Aljawini, N., Alshehri, A. H., Albahlal, H. N., & Alghamdi, S. S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156206 · Cited by 3
Inflammation and detection: Rethinking the biomarker landscape in gastric cancer
Parang, K., & Paydary, K. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i9.109717 · Cited by 2
Verlicchi, A., Canale, M., Chiadini, E., Cravero, P., Urbini, M., Andrikou, K., Pasini, L., Flospergher, M., Burgio, M. A., Crinò, L., et al. (2023) · Life · doi:10.3390/life13091915 · Cited by 2
Simulating cell-free chromatin using preclinical models for cancer-specific biomarker discoveryPreprint
Michino, S. D. D., Main, S. C., Penny, L., Kridel, R., Cescon, D. W., Hoffman, M. M., Lupien, M., & Bratman, S. V. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.16.567416 · Cited by 2
Clinical Application Guidelines for Blood-Based Circulating Tumor DNA Assays
Lee, J., Cho, E. H., Kim, B., Hong, J., Kim, Y., Kim, Y., Jang, J., Lee, S., Kong, S., Lee, W., et al. (2024) · Laboratory Medicine Online · doi:10.47429/lmo.2024.14.3.176 · Cited by 1
Godfrey, T. E., Kintsurashvili, E., Rasic, G., Kaur, J., D’Amato, C., & Meltzer, R. H. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2025.01.004
Wang, X., Li, Z., Chang, Y., Li, S., Wu, W., Chang, F., Chang, Y., Zhu, D., Gong, D., Zhang, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14457-6 · Cited by 1
Zhan, Y., Ruan, X., Wu, Y., Chun, T. T. S., Yao, C., Shi, R., Liu, J., Ali, S., Ma, R., Huang, D., et al. (2025) · JMIR Research Protocols · doi:10.2196/72597 · Cited by 1
Lazare, S., Gu, Z., Earland, N. J., Harmon, M. A., Pacula, M., Rivera, M., Tellis, A., Whitfield, D., Benson, A., Gerndt, S. P., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1221 · Cited by 3
Suda, K., Yoshida, Y., Sato, H., Ohara, S., Hamada, A., Yotsukura, M., Shiraishi, K., Hamamoto, R., Chiba, Y., Kohno, T., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0186 · Cited by 1
Fei, K., Zhao, J., Xu, J., Duan, J., Li, C., Xie, W., Zhong, J., Wang, G., Xu, Y., Sun, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202506565 · Cited by 1
Oncogene Mutations: The Shared Antigen Vaccines That Work?
Paredes, R., Haldar, S. D., Pant, S., & O'Reilly, E. M. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-111400 · Cited by 1
Liu, J., Wu, Z., Zhou, L., Shen, Y., Wu, X., Liang, J., Shao, Y., Liu, P., Li, Z., Hu, B., et al. (2025) · npj Flexible Electronics · doi:10.1038/s41528-025-00518-0 · Cited by 1
Chinese expert consensus on precision diagnosis and treatment of refractory tumors
Wang, L., Zhang, Y., Shang, Y., Lu, Y., Hu, H., Wang, G., & Wang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105109 · Cited by 1
Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection
Jiménez-Munárriz, B., Urtecho, S. B., Rabey, M. R., & Leighl, N. B. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-001002 · Cited by 1
Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma
Kwon, W., Lee, Y. J., & Song, Y. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083474 · Cited by 1
Circulating tumor DNA (ctDNA) in early-stage NSCLC: a new frontier in precision oncology
Masini, S., Fila, M., Michelini, A., Vinciguerra, M., Rudini, N., Destro, A., Rossi, S., Lorenzi, E., Santoro, A., Toschi, L., et al. (2026) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2025.136 · Cited by 1
Single-nucleotide variant profiling in liquid biopsy with RECO-Cas
Guo, C., Zhang, S., YERRAMSETTI, R. C., Zhang, J., Guan, X., Yang, R., Hou, C., Pei, M., Schalper, K. T., Liu, X., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed1757 · Cited by 1
Wang, C., geng, X., Cheng, X., Ren, R., Jin, L., Sheng, Z., Li, S., Zang, M., & Zhang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802037 · Cited by 1
Vijayakumar, S., Lewis, S., Matrana, M. R., Vasquez, R., Singh, A., Duesbery, N. S., Collier, A. B., Larned, Z., Barr, J., Orr, W. R., et al. (2026) · Current Oncology · doi:10.3390/curroncol33060342 · Cited by 1
Saeed, A., Yothers, G., Puhalla, S., Tojjari, A., Rastogi, P., Freeman, T. J., Mathias, M. D., Seebach, F. A., Wolmark, N., & George, T. J. (2026) · Future Oncology · doi:10.1080/14796694.2026.2688569 · Cited by 1
Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy
Heidrich, I., Urhahn, S., Gebhardt, C., Smit, D. J., & Pantel, K. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01056-9 · Cited by 1
Liu, Y., Wang, M., Chen, D., Tan, Y., Zhang, X., & Wang, X. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03616-1 · Cited by 1
Hlauschek, D., Dandachi, N., Gnant, M., Parsons, H., DeMichele, A. M., Heitzer, E., Rinnerthaler, G., & Balić, M. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106407 · Cited by 1
Minimal Residual Disease Testing in Solid Tumors
Turner, S. A., & Muthusamy, S. (2023) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2023.07.006 · Cited by 1
Remón, J., Lopez, A., Planchard, D., & Besse, B. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113369 · Cited by 1
Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value
Igder, S., Zamani, M., Fakher, S., Siri, M., Ashktorab, H., Azarpira, N., & Mokarram, P. (2024) · Disease Markers · doi:10.1155/2024/9943412 · Cited by 1
Narayanan, S., Wang, Y., & Gurney, H. (2024) · Onco · doi:10.3390/onco4040023 · Cited by 1
What the Clinician Needs to Know About Laboratory Analyses of Circulating Tumor DNA
Jacobsen, C. M., do Canto, L. M., Kahns, S., Hansen, T. F., & Andersen, R. F. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.01.003 · Cited by 1
Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLCPreprint
Zhang, L., Wu, J., Liu, Z., Huang, T., Wang, Y., Song, M., Song, T., Zhang, X., Li, X., & Long, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1509960/v1 · Cited by 1
The expanding role of circulating tumor DNA in resectable non–small cell lung cancer
Morgensztern, D. (2024) · Cancer · doi:10.1002/cncr.35268 · Cited by 1
HIBRID: Histology and ct-DNA based Risk-stratification with Deep LearningPreprint
Loeffler, C. M. L., Bando, H., Sainath, S., Muti, H. S., Jiang, X., van Treeck, M., Reitsam, N. G., Carrero, Z. I., Nishikawa, T., Misumi, T., et al. (2024) · medRxiv · doi:10.1101/2024.07.23.24310822 · Cited by 1
Lazare, S., Gu, Z., Earland, N. J., Harmon, A., Pacula, M., Rivera, M., Tellis, A., Whitfield, D., Benson, A., Gerndt, S. P., et al. (2024) · medRxiv · doi:10.1101/2024.09.27.24314491 · Cited by 1
Response to Letter to the Editor
Jun, S., Shukla, N. A., Hanna, N. H., & Diehn, M. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1425 · Cited by 1
Self-citationGunaratne, R., Zhou, C. M., Rajaram, S., Tai, J. W., Tanaka, K. L., Tiwari, C., Yang, E., Kim, S., Gao, G., Yin, R. R., et al. (2026) · medRxiv · doi:10.64898/2026.01.28.26344873 · Cited by 1
Roberts, H. J., Comeau, H., Klega, K., DuBois, S. G., Lazo de la Vega, L., Ceca, E., Mullen, E. A., Smith, G. A., Tukachinsky, H., Huang, R. S. P., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01125
Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026) · Cells · doi:10.3390/cells15141271
Martin-Alonso, C., Tabrizi, S., Xiong, K., Blewett, T., Patel, S., An, Z., Sridhar, S., Bekdemir, A., Shea, D., Amini, A. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.13.524003
Taking on Solid Tumor Minimal Residual Disease (MRD)
(2023) · Inside Precision Medicine · doi:10.1089/ipm.10.01.12
Cell-Free DNA Liquid Biopsy: The Epitome of Personalized Precision Oncology
Chaudhuri, A. A. (2023) · Radiation Research · doi:10.1667/rade-23-00044.1
Yang, P., Zhang, Y., Xia, L., Mei, J., Fan, R., Huang, Y. S., Liu, L., & Chen, W. (2023) · PubMed Central · doi:10.7507/1001-5515.202303039 · Cited by 1
Potential of circulating tumour DNA as a biomarker in liquid biopsy
Dimitrov, D. K., Ivanov, H. Y., Miteva-Marcheva, N., & Stoyanova, V. K. (2023) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2023.2287236
Special Issue “Molecular Advances in Cancer Genetics 3.0”
Bruno, W., & Ghiorzo, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052717
Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., Yang, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616578
Lin, C., Chen, Z., Kang, F., Hu, J., Huang, L., Liao, C., Lai, J., Huang, Y., Wang, Z., Tian, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23435188
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815156
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815153
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815144
Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis
Ni, H., Wang, Z., Tang, Y., Lu, J., Zhu, Z., Qiu, Y., Chen, Z., & Wang, Z. (2024) · Cell Biology International · doi:10.1002/cbin.12230
Enhancing liquid biopsies are a promising approach for the early detection of cancer
Xu, R., Huang, C., Pan, Q., Zhu, Y., & Qu, S. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0019
A Promising Step Forward With Giant Leaps Ahead
Shaverdian, N., Li, B. T., Isbell, J. M., & Chaft, J. E. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.08.002
What Is Best Liquid Remnant for Resected Early-Stage Non-small Cell Lung Cancer?
Lanuti, M. D. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.06.029
d'Alessandro, A., Deaconu, A. F., Mandolesi, S., Fabrizio, F. P., Lombardi, M., Liguori, G., Pepe, G., Marino, N., Stingi, A., d'Alessandro, A., et al. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2024.63
The ctDNA revolution: Insights on cancer care: A narrative review
Gohil, K. M., Reddy, J. P., Mulla, S. K., Singh, R., Shah, R., & Gohil, S. M. (2024) · Bioinformation · doi:10.6026/9732063002001287
Is Assessment of cDNA Useful in Surveillance After Lung Cancer Resection
Chen, K., He, Y., Li, Z., & Wang, J. (2024) · Difficult decisions in surgery: an evidence-based approach · doi:10.1007/978-3-031-78663-1_30
The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility
Lucas, M. W., & Chia, S. (2025) · Canadian oncology today. · doi:10.58931/cot.2025.2130
Oliva, M., Llop, S., Arribas, L., & Mesı́a, R. (2025) · Springer eBooks · doi:10.1007/978-3-031-84539-0_18
Makiguchi, T., Tanaka, H., Morikawa, K., Hirata, A., Itani, H., Tanzawa, S., Watanabe, K., Yasuda, H., Horiuchi, K., Nakagawa, H., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100952
LIQUID BIOPSY: REVOLUTIONIZING MINIMAL RESIDUAL DISEASE DETECTION IN LUNG CANCER
Kaus, M., Adamska, H., Cudziło, Z., Grzesik, K., Klepacz, N., Malicka, M., Nowak, W. E., Pilarczyk, K., Rabęda, A., & Sawczuk, H. (2025) · Health Problems of Civilization · doi:10.5114/hpc.2025.151862
Li, Y., Ao, C., & Wu, S. B. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.06.075
A new reality of molecular surveillance for resected lung cancer
Shi, S., & Christopoulos, P. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-523
Wang, X., Guan, Y., Gao, W., Lai, X., Cao, W., Zhu, X., Zeng, X., Liu, Y., Wang, S., Liu, R., et al. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013443
Guan, Y., Han, L., & Chen, X. (2025) · Talanta Open · doi:10.1016/j.talo.2025.100575
Hashimoto, T., Hirano, H., Takashima, A., Sekine, S., Kanato, K., Mizusawa, J., Fukuda, H., Tsukamoto, S., & Kanemitsu, Y. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100212
Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., Yang, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616572
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815162
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815150
Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., Yang, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616569
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815147
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815159
Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., Yang, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616575
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815141
Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., Tu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815165
Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer
Patel, S. P., Gainor, J. F., Kao, S. C.-H., Lee, S.-H., Mok, T. S. K., Shah, R., Zhou, C., & Peters, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1690367
Tripathy, S., Gaur, A., Jagadeb, M., Swarup, V., Gupta, N. M., Kumar, U., Das, S., & Jana, M. K. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2025.12.006
Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma
Wu, J., Liu, Z., Huang, T., Wang, Y., Yu, J., Li, S., Xie, K., Kuang, S., Liu, C., & Zhang, L. (2026) · Communications Medicine · doi:10.1038/s43856-026-01386-z
Advancing Cancer Management: The Dual Diagnostic‐Prognostic Potential of Nucleic Acid Biomarkers
Shao, Y., Jin, Q., Zhang, J., Chen, Y., Wang, G., & Ye, B. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70178
Yilmaz, M., Zaheer, S., MANSUKHANI, M. M., & Hsiao, S. J. (2026) · Surgical pathology clinics · doi:10.1016/j.path.2026.01.002
Kim, J., Ye, S., Kwak, J., Choi, D., Kim, S., Jeong, H. J., Hong, E., Lee, J. W., Kim, S., Won, Y.-J., et al. (2026) · medRxiv · doi:10.64898/2026.03.09.26347910
Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management
Kim, J., Morceau, F., Kwon, Y., & Shin, Y. J. (2026) · Cancers · doi:10.3390/cancers18071049
Wang, Z., Gui, L., (132223), Y. Z., Huang, S., Wang, S., Zhang, X., Zhang, F., Yan, X., Zhang, Z., Liu, S. H., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1748855
Huang, Z., He, J., Li, Y. L., Xu, Z., Peng, H., Gao, X., Zhou, H., Guo, J., & Yang, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835413
Gu, R.-T., Liu, T., Piao, Z., Jin, H., Wang, X.-W., & Li, X. R. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.120942
Metadata
- Authors
- Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Alizadeh, Ash A.
- Diehn, Maximilian
- Venue
- Cancer Discovery
- Published
- 2021-12-01
- Volume
- 11
- Issue
- 12
- Pages
- 2968-2986
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8976700
- OpenAlex
- W3214322235
- Cited by
- 325
- References
- 114
- Citations by year
- 2026: 66 · 2025: 75 · 2024: 74 · 2023: 81 · 2022: 28 · 2021: 1
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (5R25CA180993)
- Postdoctoral Research Fellowship (134031-PF-19-164-01-TBG)
- Leukemia and Lymphoma Society NCI (R01CA257655, R01CA233975, R01CA188298)
- NCI (R01CA188298, R01CA233975, R01CA244526, R01CA254179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- circulating tumor DNA, minimal residual disease, solid tumors, recurrence prediction, liquid biopsy, adjuvant therapy, treatment response monitoring, liquid biopsy biomarkers, personalized treatment
- MeSH terms
- Circulating Tumor DNA, Humans, Neoplasm Recurrence, Local, Biomarkers, Tumor, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
